Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Shea

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Plos One|March 3, 2016
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in MalawiSatish Gopal, Yuri Fedoriw, Bongani Kaimila, et al.
British Journal of Haematology|November 20, 2018
Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohortMatthew S Painschab, Edwards Kasonkanji, Takondwa Zuze, et al.
Blood|February 18, 2014
Increased BCR responsiveness in B cells from patients with chronic GVHDJessica L Allen, Prasanthi V Tata, Matthew S Fore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 15, 2018
Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled TrialMahasweta Gooptu, Haesook T Kim, Yi-Bin Chen, et al.
Blood|August 17, 2012
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathwaysJessica L Allen, Matthew S Fore, Jenna Wooten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Blood|August 2, 2003
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphomaKoen van Besien, Fausto R Loberiza, Ruta Bajorunaite, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Plos One|March 3, 2016
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in MalawiSatish Gopal, Yuri Fedoriw, Bongani Kaimila, et al.
British Journal of Haematology|November 20, 2018
Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohortMatthew S Painschab, Edwards Kasonkanji, Takondwa Zuze, et al.
Blood|February 18, 2014
Increased BCR responsiveness in B cells from patients with chronic GVHDJessica L Allen, Prasanthi V Tata, Matthew S Fore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 15, 2018
Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled TrialMahasweta Gooptu, Haesook T Kim, Yi-Bin Chen, et al.
Blood|August 17, 2012
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathwaysJessica L Allen, Matthew S Fore, Jenna Wooten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesRobert Z Orlowski, Thomas E Stinchcombe, Beverly S Mitchell, et al.
Blood|August 2, 2003
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphomaKoen van Besien, Fausto R Loberiza, Ruta Bajorunaite, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Pageof 8